BioLamina

Stephen Gusikowski

🇦🇺 Australia

5.7

Reviewed: June 10, 2024

• - Project Management
• - 12 weeks March - May 2024
• - Biotech Company

Communication from the project management team was poor, with frequent missed deadlines. This caused significant frustration on our end, as we had to repeatedly chase them for updates. The project eventually got back on track, but the delays were problematic.

Dr. Nichole Streich

🇷🇺 Russia

9.1

Reviewed: April 6, 2024

• - HTA Submission
• - 8 weeks February - March 2024
• - Biotech Company

The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.

Jeannette Conroy

🇨🇳 China

9.3

Reviewed: March 12, 2024

• - Market Access Strategy
• - 6 weeks January - February 2024
• - Pharmaceutical Company

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.

Brendan Carroll V

🇩🇪 Germany

9.2

Reviewed: August 20, 2024

• - Regulatory Strategy Consulting
• - 4 weeks July - August 2024
• - Biotech Startup

The regulatory strategy consulting services were thorough and provided us with a clear pathway to regulatory approval. The team's deep understanding of the regulatory landscape was invaluable, and their strategic advice was spot on.

Dallas Wunsch

🇰🇷 South Korea

5.4

Reviewed: October 3, 2024

• - Process Development
• - 14 weeks June - September 2024
• - Biotech Company

The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.